Retatrutide Cycle Length UAE: 12 vs 24 vs 48 vs 72 Weeks — Buy in Dubai 2026

Why Cycle Length Is the First Protocol Decision

Most retatrutide questions cluster around dose — 4, 8 or 12 mg — but the bigger structural decision is how many weeks the cycle runs. Cycle length determines vial count, total cost, when results are evaluated, when side-effect resolution is expected, and whether the curve has any chance of reaching its asymptote. A 12-week cycle and a 72-week cycle are essentially different experiments on the same molecule.

Retatrutide (LY3437943) is a triple agonist of GLP-1, GIP and glucagon receptors developed by Eli Lilly (Coskun et al., 2022, Cell Metabolism). The published evidence base — Jastreboff 2023 for obesity and Rosenstock 2023 for type 2 diabetes — used 48-week and 36-week designs respectively. Any cycle shorter than 24 weeks is operating below the trial floor; anything beyond 48 weeks is operating above the evidence ceiling and into projection.

What Jastreboff 2023 Actually Showed at 48 Weeks

The phase 2 obesity trial randomised 338 adults with BMI 30+ (or 27+ with weight-related comorbidity) to placebo or one of four maintenance dose targets: 1, 4, 8 or 12 mg weekly subcutaneous. The titration phase was the first 12–24 weeks; maintenance ran to week 48.

The critical observation: at 48 weeks the 4/8/12 mg arms had not reached plateau. The slope was shallower than during titration but still negative. That is what makes 48 weeks the published floor for evaluating effect size — not because the plateau was hit, but because the trial stopped there.

The Four Standard Cycle Lengths

12-Week Cycle — Feasibility Only

• Captures titration through approximately the 4 mg step
• Maintenance phase is essentially zero — you are still ramping at the endpoint
• Weight change is dominated by titration effects, not steady-state pharmacology
• Total vials: 1 to 2 (5 mg or 10 mg)
• Use case: tolerance check, GI profile evaluation, baseline metabolic measurement before committing to a longer cycle

24-Week Cycle — Short Evaluation

• Full titration plus ~8 weeks at the chosen maintenance dose
• Captures roughly 60–70% of the 48-week effect size at any given dose
• Side-effect resolution typically observed within this window
• Total vials: 2 to 4 depending on maintenance dose
• Use case: first cycle for new researchers, half-year evaluation windows, conservative budget planning

48-Week Cycle — Evidence-Matched Standard

• Matches the Jastreboff 2023 published protocol exactly
• Captures full titration plus ~24 weeks of maintenance
• Most reproducible against published data
• Total vials: 4 to 8 depending on maintenance dose
• Use case: default research cycle, anything intended to be compared against the published evidence base

72-Week Cycle — Extended Protocol

• Beyond the published evidence base — extrapolation territory
• Class precedent from semaglutide STEP 5 (104 weeks) suggests continued slow descent toward asymptote
• Useful when 48-week endpoint still showed clear downward slope
• Total vials: 6 to 12 depending on maintenance dose
• Use case: subjects with high starting BMI who still have runway at week 48, long-term metabolic adaptation studies

Tolerance vs Plateau — Two Different Phenomena

Researchers planning long cycles often ask whether retatrutide "stops working." It is important to separate two distinct concepts:

Receptor tolerance would mean diminished pharmacological response at the same dose. This has not been documented for retatrutide in published trials. The receptor binding profile remains stable; signal transduction does not measurably down-regulate over the 48-week evidence window.

Metabolic plateau is energy-balance arithmetic. As body mass falls, basal metabolic rate falls with it (Müller et al., 2015, American Journal of Clinical Nutrition). The same caloric deficit that produced 1 kg/week at baseline produces less at lower mass. This is what produces the asymptotic curve, not receptor desensitisation.

Practically: if a long cycle is showing diminished descent, the answer is rarely "increase the dose to overcome tolerance" — it is usually "the energy balance equation has shifted." See our companion piece on retatrutide plateau strategies.

Plateau Patterns Across the GLP-1 Class

Cross-trial comparison gives a useful map of when plateaus typically appear:

• Semaglutide 2.4 mg (STEP 1, Wilding 2021): weight loss plateau at approximately week 60 of 68 in most subjects.
• Tirzepatide 15 mg (SURMOUNT-1, Jastreboff 2022): curve still descending at week 72 endpoint.
• Retatrutide 12 mg (Jastreboff 2023): curve still descending at week 48 endpoint — earliest available data point.

The pattern across the class is that higher-efficacy agents reach plateau later. Extrapolating cautiously, retatrutide plateau likely sits beyond week 60 at maintenance doses of 8–12 mg, which is part of the rationale for the 72-week extended cycle.

Long vs Short Cycle Trade-offs

Long Cycle Advantages

• Larger total effect size — more of the curve captured
• Better evidence-matched (48 weeks specifically replicates Jastreboff)
• Per-week side-effect burden drops once maintenance is reached
• Lower cost per week of effect (titration overhead amortised over longer cycle)

Long Cycle Disadvantages

• Higher absolute vial count and total spend
• Greater logistics burden — cold-chain storage for 6+ months
• Longer commitment if subject discontinues mid-cycle
• Plateau risk: latter weeks may show minimal additional effect

Short Cycle Advantages

• Lower absolute spend
• Faster evaluation cycle — pivot or extend based on early data
• Easier to abort if tolerability fails

Short Cycle Disadvantages

• Effect size capped well below published trial endpoints
• Higher proportion of cycle spent in titration (highest side-effect burden, lowest steady-state effect)
• Post-cycle regain may erase a larger fraction of total loss

Cycle Cost Planning — UAE Vial Counts

REVIVE LAB stocks retatrutide as 5 mg and 10 mg vials. Total vial counts depend on maintenance dose and titration schedule. Approximate counts for a standard 4-week-per-step titration:

Researchers running 48-week or 72-week cycles typically pre-order in batches of 3–6 vials to lock in pricing and reduce shipment count. REVIVE LAB Dubai holds continuous stock, so re-orders during a cycle ship next-day across the UAE — no need to over-stock if storage capacity is limited. For dose-step mechanics, see the retatrutide titration schedule UAE guide.

Post-Cycle: What Happens When You Stop

The STEP 4 trial of semaglutide (Rubino et al., 2021, JAMA) randomised subjects after 20 weeks of titration to continue or switch to placebo. The continue group lost an additional 7.9%; the placebo-switch group regained 6.9%. By 12 months post-cessation, roughly two-thirds of lost weight had returned.

No equivalent post-cessation trial has been published for retatrutide as of mid-2026, but the class pattern is consistent enough that researchers should plan for partial regain after cycle end. Three common post-cycle approaches:

1. Hard stop. Cycle ends, no maintenance. Expect class-typical regain pattern. Acceptable for fixed-endpoint research.
2. Maintenance microdose. Drop to 1–2 mg weekly post-cycle. Less published evidence but biologically rational.
3. Taper. Step down through previous titration doses in reverse over 4–8 weeks. Reduces post-cessation appetite rebound.

UAE Delivery & Sourcing — Buy Retatrutide UAE with 24h Delivery

REVIVE LAB operates from Dubai with a continuous-stock model and 24h delivery to all seven emirates. For researchers committing to a 24-week or 48-week cycle, sourcing logistics matter as much as the protocol itself — interruptions mid-titration force re-ramping and waste evidence-matched vial inventory.

Delivery Coverage

• Dubai: same-day delivery for orders placed before 1pm; otherwise next-day
• Abu Dhabi: 24h delivery, cold-chain insulated
• Sharjah, Ajman: 24h delivery
• Ras Al Khaimah, Umm Al Quwain, Fujairah: next-day delivery

Cold-Chain Logistics

Lyophilised retatrutide is stable at room temperature for several weeks but UAE summer ambient temperatures regularly exceed 45°C, which compresses the safe window. REVIVE ships all vials in insulated boxes with gel packs and recommends immediate refrigeration on arrival. For reconstituted vials, refrigerated shelf life is approximately 28 days — full storage guidance in our UAE peptide storage guide.

Ordering Process

1. Place order on the retatrutide product page — select 5 mg or 10 mg vial count
2. Pay via card, bank transfer or cash on delivery
3. Orders before 4pm Dubai time dispatch same-day
4. Track via SMS — most UAE addresses delivered within 24h
5. HPLC certificate of analysis emailed with dispatch confirmation

For the broader peptide catalogue stocked in Dubai see peptides UAE.

Cycle Selection Heuristic

A practical decision rule based on cycle length and research goal:

• Never run before: 12-week feasibility cycle at 4 mg target. Confirm tolerance, then commit to a longer cycle.
• Default research cycle: 48 weeks at 8 mg maintenance — matches Jastreboff 2023 middle dose arm, best evidence-replication value.
• Maximum effect research: 48-72 weeks at 12 mg maintenance — replicates top-dose arm and extends into projection territory.
• Budget-constrained: 24 weeks at 4 mg — captures ~60% of evidence-matched effect at ~30% of vial cost.